Docetaxel
Docetaxel structure
|
Common Name | Docetaxel | ||
|---|---|---|---|---|
| CAS Number | 114977-28-5 | Molecular Weight | 807.879 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 900.5±65.0 °C at 760 mmHg | |
| Molecular Formula | C43H53NO14 | Melting Point | 186-192 °C (dec.) | |
| MSDS | USA | Flash Point | 498.4±34.3 °C | |
|
Androgen receptor (AR) inhibitor ErbB3-binding protein-1 (Ebp1) is not targeted by the newly identified AR controlling signaling axis heat-shock protein HSP27 and microRNA miR-1 in prostate cancer cells.
World J. Urol. 33(3) , 323-7, (2015) Androgen receptor (AR) networks are predominantly involved in prostate cancer (PCa) progression; consequently, factors of AR regulation represent promising targets for PCa therapy. The ErbB3-binding protein 1 (Ebp1) is linked to AR suppression and chemoresist... |
|
|
Immediate and transient phosphorylation of the heat shock protein 27 initiates chemoresistance in prostate cancer cells.
Oncol. Rep. 32(6) , 2380-6, (2014) Drug resistance minimizes the effects of prostate cancer (PC) chemotherapy with docetaxel and is generally considered to be associated with the expression of heat shock protein (HSP) 27 including various cytoprotective pathways. In the present study, we inves... |
|
|
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Mol. Cancer Ther. 14(1) , 48-58, (2015) Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears dependent on the PI3Kβ isoform. Inhibitors of PI3Kβ have potential to reduce growth of tumors in which loss of PTEN drives tumor progression. We have developed a small-molecul... |
|
|
Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells.
PLoS ONE 9(8) , e103109, (2014) Despite its side-effects, docetaxel (DTX) remains a first-line treatment against castration resistant prostate cancer (CRPC). Therefore, strategies to increase its anti-tumor efficacy and decrease its side effects are critically needed. Targeting of the const... |
|
|
Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer.
ACS Nano 8(6) , 6056-65, (2014) High-throughput production of nanoparticles (NPs) with controlled quality is critical for their clinical translation into effective nanomedicines for diagnostics and therapeutics. Here we report a simple and versatile coaxial turbulent jet mixer that can synt... |
|
|
Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.
Mol. Pharm. 11(7) , 2040-50, (2014) The lack of effective therapies for bone metastatic prostate cancer (PCa) underscores the need for accurate models of the disease to enable the discovery of new therapeutic targets and to test drug sensitivities of individual tumors. To this end, the patient-... |
|
|
Molecular cloning and functional characterization of a rainbow trout liver Oatp.
Toxicol. Appl. Pharmacol. 280(3) , 534-42, (2014) Cyanobacterial blooms have an impact on the aquatic ecosystem due to the production of toxins (e.g. microcystins, MCs), which constrain fish health or even cause fish death. However the toxicokinetics of the most abundant toxin, microcystin-LR (MC-LR), are no... |
|
|
The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
Mol. Cancer Ther. 13(12) , 2827-39, (2014) Insulin-like growth factor (IGF) signaling is associated with castrate-resistant prostate cancer (CRPC) progression. Insulin receptor substrates 1 and 2 (IRS1/2) mediate mitogenic and antiapoptotic signaling from IGF1 receptor (IGF1R), insulin receptor, and o... |
|
|
Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones.
Anticancer Drugs 26(1) , 90-100, (2014) The efficacy of gemcitabine (GEM), a standard treatment agent for pancreatic cancer, is insufficient because of primary or acquired resistance to this drug. Patients with tumors intrinsically sensitive to GEM gradually acquire resistance and require a shift t... |
|
|
ERG induces taxane resistance in castration-resistant prostate cancer.
Nat. Commun. 5 , 5548, (2014) Taxanes are the only chemotherapies used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Despite the initial efficacy of taxanes in treating CRPC, all patients ultimately fail due to the development of drug resistance. In this s... |